Event

Vallerie V. McLaughlin

MD
Director of Pulmonary Hypertension Program, University of Michigan;University of Michigan;University of Michigan Medical Center

Brian Hartline

MD
Actelion Pharmaceuticals US, Inc.

Michael Keating

PharmD, RPh
Actelion Pharmaceuticals US, Inc.

Kelly Chin

MD
Univ of Texas Southwestern Medical Center;University of Texas Southwestern;University of Texas, Southwestern Medical Center;UT Southwestern;UT Southwestern Medical Center

Anna Hemnes

MD
Vanderbilt Univ;Vanderbilt University;Vanderbilt University Medical Center

Kristin B. Highland

MD
Cleveland Clinic

Murali M. Chakinala

MD
Washington Univ;Washington University;Washington University School of Medicine

Carol Zhao

MS
Actelion Pharmaceuticals US, Inc.

Harrison W. Farber

MD
Boston Univ Sch of Med;Boston University School of Medicine;Pulmonary Center, Boston University School of Medicine

Nick H. Kim

MD
UC San Diego Health;Univ of California San Diego;University of California San Diego;University of California San Diego Medical Center;University of California, San Diego

Transitions from Inhaled, Intravenous, Subcutaneous, or Oral Prostacyclins to Selexipag: Interim Data from the SPHERE Registry (SelexiPag: tHe UsErs dRug rEgistry)